VolitionRx Limited (NYSE American: VNRX) has entered into a collaboration with Sysmex (TYO: 6869) to optimize Volition’s Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform, according to a press release. The agreement supports Volition’s strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization.
The collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. Volition believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring and address a commercial opportunity with an estimated total addressable market of $3.8 billion.
Volition is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For further information, visit the company’s website at https://volition.com/. To view the full press release, visit https://ibn.fm/TSMG4.
This collaboration with Sysmex marks a significant step toward bringing the Nu.Q® NETs assay to market, potentially providing clinicians with a valuable tool for diagnosing and monitoring NETosis-related diseases. The partnership leverages Sysmex’s global reach and expertise in diagnostics, which could accelerate regulatory approvals and adoption of the assay. With an estimated $3.8 billion addressable market, the successful development and commercialization of the Nu.Q® NETs assay could have substantial implications for patient care and Volition’s financial performance.
